A personalised mRNA vaccine for melanoma, the deadliest form of skin cancer, is expected to be approved for use in the US, Europe and the UK next year.
The vaccine is designed to stimulate immune responses against genetic mutations that are unique to an individual’s cancer. When used alongside standard treatment in a late-stage trial, it substantially cut the risk of cancer recurrence or death within the next two years.
